Table 3.

Physicochemical properties, food effect data and measured flux of the studied compounds

Drugs	BCS Class	log P	Solubility ratio	Observed AUC Ratio	Observed Cmax Ratio	FE	Dose used in clinical data	Dose used flux study	Flux Fe (±SD; n=3)	Flux Fa (±SD; n=3)	Flux Ratios
			(Fed/Fasted)	(Fed/Fasted)	(Fed/Fasted)		(mg)	(mg)			(Fed/Fasted)
Amiodarone [27] (early)1	II	7.8	2.23	2.36	3.68	positive	600	200	0.073 ± 0.001	0.017± 0.003	4.25
Amiodarone (late)2	II	7.8	2.23	2.36	3.68	positive	600	200	1.277± 0.109	0.579 ± 0.095	2.21
Celecoxib [29]	II	3.02	2.24	1.19	1.29	positive	200	50	0.632 ± 0.077	0.186 ± 0.021	3.4
Clopidogrel bisulfate [43]	II/IV	4.2	3.85	1.02	0.79	none	75	75	2.168 ± 0.323	1.751 ± 0.540	1.24
Danazol [30]	II	4.7	3.43	3.13	2.73	positive	100	100	0.352 ± 0.063	0.081 ± 0.016	4.35
Fluoxetine HCl [41]	I	4.5	1.17	0.96	0.85	none	40	40	0.85 ± 0.01	1.77 ± 0.15	0.5
Furosemide [32]	IV	2.56	0.23	1.18	0.67	negative	40	80	0.208 ± 0.036	0.018 ± 0.003	11.48
Griseofulvin [31]	II	2.2	1.24	1.7	2.2 (4 h) 1.7 (8 h)	positive	1000	125	0.218 ± 0.009	0.205 ± 0.011	1.06
Isoniazid [37]	I	-0.52	n/a	0.88	0.49	negative	300	300	0.020 ± 0	0.020 ± 0	1.02/0.92
Nefazodone HCl [38]	II	3.5	1.52	0.78	0.93	negative	200	50	1.077 ± 0.084	0.521 ± 0.179	2.07
Nefazodone HCl suspension	II	3.5	1.52	0.78	0.93	negative	200	100	1.923 ± 0.547	2.610 ± 0.618	0.74
Nifedipine [44]	II	3.17	3.2	1.02	0.74	none	10	25	0.235 ± 0.028	0.233 ± 0.073	1.01
Zidovudine [42]	III	0.13	n/a	0.9	0.3	negative	100	200	0.034 ± 0.002	0.037 ± 0.007	0.92

¹ “early” flux refers to the initial appearance rate in the acceptors. The early flux was calculated using the data in the first 2 hours of the experiment, selecting time interval for each media excluding lag time.

² “late” flux corresponds to the appearance rate during the later time points in the acceptor. The late flux was calculated using the data in the 2.5-9 hours’ time interval, selecting the intervals guided by linearity of the concentration-time profiles in the receptor